Long-term Safety Monitoring and Efficacy Status of Infliximab and its Biosimilars in Psoriasis Management

被引:0
作者
Sharma, Kiran [1 ]
Ghai, Roma [2 ]
Rana, Neha [3 ]
机构
[1] Charles Sturt Univ, Sch Dent & Med Sci, 346 Leeds Parade, Orange, NSW 2800, Australia
[2] Delhi NCR, KIET Grp Inst, KIET Sch Pharm, Ghaziabad Meerut Rd, Ghaziabad 201206, Uttar Pradesh, India
[3] Noida Int Univ, Sch Pharm, Yamuna Expressway, Greater Noida, India
关键词
Infliximab; biosimilars; TNF; psoriasis; inflammation; infusion therapy; PASI; PLAQUE-TYPE PSORIASIS; NATIONAL PSORIASIS; PUSTULAR PSORIASIS; FOUNDATION GUIDELINES; INFLAMMATORY DISEASES; AMERICAN ACADEMY; MEDICAL BOARD; DOUBLE-BLIND; FC GLYCANS; THERAPY;
D O I
10.2174/0115748863320685240830092746
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Infliximab (INF), a murine human monoclonal antibody, is a substantially more successful biologic than topical drugs for treating mild to severe psoriasis because it clears the skin rapidly due to its fast onset of action. Loss of responsiveness over time and some adverse effects, especially the experience of infusion reactions, are the major causes of non-compliance with INF medication. Therefore, evaluation of the long-term reliability of anti-tumor necrosis factor (TNF) medications is necessary for the assessment of the risks associated with long-term anti-TNF therapy. For psoriasis, there are registered safety statistics; however, these individuals might not receive the same level of care as those in a randomized study. Few assessments of the safety of anti-TNF medications across indications, including their biosimilars, are present, but it's still unknown how anti-infliximab antibodies arise and produce harmful effects. INF biosimilars, when subjected to human studies to reduce cost and improve access, provide therapeutic benefits with associated adverse events, showing variations in incidence depending upon varying patient populations and no new safety indications. During therapy, certain individuals develop antibodies against INF, which are believed to be linked to a loss of response (LOR). Additional research aimed at identifying individuals who are susceptible to treatment resistance is likely to assist doctors in accurately selecting the appropriate candidates for anti-TNF-alpha therapy and enhancing the long-term effectiveness of the treatment. From clinical studies, we expect to learn about how to utilize INF or its biosimilars more effectively in the management of psoriasis. Therefore, the paper focuses on the efficacy and safety monitoring of INF and developed biological therapies.
引用
收藏
页码:271 / 286
页数:16
相关论文
共 50 条
[41]   Long-term efficacy and safety of once daily treatment of chronic plaque psoriasis with tacalcitol ointment [J].
vandeKerkhof, P ;
vanderVleuten, C ;
Gerritsen, M ;
Glade, C ;
Luger, T ;
Werfel, T ;
Kluss, B .
EUROPEAN JOURNAL OF DERMATOLOGY, 1997, 7 (06) :421-425
[42]   Long-term efficacy and safety of infliximab and cyclosporine combination therapy for refractory uveoretinitis in Behcet's disease [J].
Katsuyama, Atsuko ;
Kusuhara, Sentaro ;
Nishisho, Ryuto ;
Matsumiya, Wataru ;
Azumi, Atsushi ;
Nakamura, Makoto .
CLINICAL OPHTHALMOLOGY, 2019, 13 :521-527
[43]   Long-term safety and efficacy of eculizumab in generalized myasthenia gravis [J].
Muppidi, Srikanth ;
Utsugisawa, Kimiaki ;
Benatar, Michael ;
Murai, Hiroyuki ;
Barohn, Richard J. ;
Illa, Isabel ;
Jacob, Saiju ;
Vissing, John ;
Burns, Ted M. ;
Kissel, John T. ;
Nowak, Richard J. ;
Andersen, Henning ;
Casasnovas, Carlos ;
de Bleecker, Jan L. ;
Vu, Tuan H. ;
Mantegazza, Renato ;
O'Brien, Fanny L. ;
Wang, Jing Jing ;
Fujita, Kenji P. ;
Howard, James F., Jr. ;
Kaya, Angela ;
Khursigara, Gus ;
Armstrong, Roisin ;
Diab, Diaa ;
Capocelli, Kelley ;
Lane, Cindy ;
Sanders, Vicky ;
Gandolfo, Ruth .
MUSCLE & NERVE, 2019, 60 (01) :14-24
[44]   Long-term safety and efficacy of imatinib in pulmonary arterial hypertension [J].
Frost, Adaani E. ;
Barst, Robyn J. ;
Hoeper, Marius M. ;
Chang, Hyuk-Jae ;
Frantz, Robert P. ;
Fukumoto, Yoshihiro ;
Galie, Nazzareno ;
Hassoun, Paul M. ;
Klose, Hans ;
Matsubara, Hiromi ;
Morrell, Nicholas W. ;
Peacock, Andrew J. ;
Pfeifer, Michael ;
Simonneau, Gerald ;
Tapson, Victor F. ;
Torres, Fernando ;
Vizza, Carmine Dario ;
Lawrence, David ;
Yang, Wei ;
Felser, James M. ;
Quinn, Deborah A. ;
Ghofrani, Hossein-Ardeschir .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (11) :1366-1375
[45]   Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis [J].
Pariser, David M. ;
Leonardi, Craig L. ;
Gordon, Kenneth ;
Gottlieb, Alice B. ;
Tyring, Stephen ;
Papp, Kim A. ;
Li, Joanne ;
Baumgartner, Scott W. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (02) :245-256
[46]   Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience [J].
Radi, Giulia ;
Campanati, Anna ;
Diotallevi, Federico ;
Rizzetto, Giulio ;
Martina, Emanuela ;
Bobyr, Ivan ;
Giannoni, Melania ;
Offidani, Annamaria .
DERMATOLOGIC THERAPY, 2021, 34 (06)
[47]   Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry [J].
Rahman, Proton ;
Starr, Michael ;
Haaland, Derek ;
Bessette, Louis ;
Teo, Michelle ;
Rampakakis, Emmanouil ;
Lehman, Allen J. ;
Nantel, Francois .
BMC RHEUMATOLOGY, 2020, 4 (01)
[48]   Long-term topical management of psoriasis: the road ahead [J].
Segaert, Siegfried ;
Calzavara-Pinton, Piergiacomo ;
de la Cueva, Pablo ;
Jalili, Ahmad ;
Lons Danic, Dominique ;
Pink, Andrew E. ;
Thaci, Diamant ;
Gooderham, Melinda .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) :111-120
[49]   Long-Term Treatment with Infliximab in Patients with Sarcoidosis [J].
Hostettler, Katrin E. ;
Studler, Ueli ;
Tamm, Michael ;
Brutsche, Martin H. .
RESPIRATION, 2012, 83 (03) :218-224
[50]   Long-term data in the treatment of psoriasis [J].
Thaci, D. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 :18-24